Compare Repligen Corporation Common Stock (RGEN) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Uranium Energy Corp — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while Uranium Energy Corp trades at $7.54 (market cap $3.82B). The key difference: Repligen Corporation Common Stock is far larger — about 3× Uranium Energy Corp's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Uranium Energy Corp for 38 Days on average.
| RGEN | UEC | |
|---|---|---|
Market Cap | $11.31B | $3.82B |
Volume | 1,216,919 | 13,882,337 |
Sector | Health | Energy |
52-Week High | $194.57 | $20.14 |
52-Week Low | $102.87 | $7.70 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $11.20B | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Uranium Energy (UEC) trades at $8.25, down 6.57% today, amid bearish technical signals despite strong analyst support. The company shows operational improvements with multi-mine expansion but faces fundamental challenges with negative net income margins (-368.62%) and declining revenue from $67M in 2025 to $37M in 2026. Recent Q4 2026 earnings beat revenue estimates but missed on EPS, while technical indicators show 18 sell signals versus 3 buy signals.
The stock presents a high-risk opportunity with Wall Street optimism (87.5% buy ratings, $16.06 consensus target) contrasting with weak financials. Key risks include unsustainable production growth, dependence on inventory sales, and cash flow challenges. Upside depends on successful execution of uranium production ramp-up and favorable government demand trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
